清肺化痰解毒方治疗痰热壅肺型重症肺炎的临床研究

Clinical Study on the Treatment of Severe Pneumonia with Phlegm-Heat Obstructing the Lung Syndrome Using the Qingfei Huatan Jiedu Formula

摘要: 目的：观察和分析清肺化痰解毒方治疗痰热壅肺型重症肺炎患者的作用机制。方法：分析我院收治的90例痰热壅肺型重症肺炎患者，分为对照组和观察组，每组45例，对照组患者给予常规西药治疗，观察组对照组治疗基础上予以清肺化痰解毒方治疗。比较两组患者的治疗前后中医症候评分、临床有效率、不良反应。结果：观察组患者治疗后的中医症候评分(咳嗽、发热、痰黄黏稠、气喘)低于对照组，差异具有统计学意义(P < 0.05)。观察组临床有效率、药物不良反应为优于对照组(95.6% vs 82.1%、8.8% vs 22%)，差异具有统计学意义(P < 0.05)。结论：清肺化痰解毒方治疗痰热壅肺型重症肺炎临床效果显著，且安全性高，值得临床推广。

Abstract: Objective: To observe and analyze the mechanism of action of Qingfei Huatan Jiedu Formula in treating patients with severe pneumonia of the phlegm-heat obstructing lung type. Methods: A total of 90 patients with severe pneumonia of the phlegm-heat obstructing lung type admitted to our hospital were analyzed and divided into a control group and an observation group, with 45 cases in each group. Patients in the control group were treated with conventional western medicine, while those in the observation group were treated with Qingfei Huatan Jiedu Formula in addition to the control group’s treatment. The TCM symptom scores (cough, fever, yellow and sticky phlegm, and wheezing), clinical efficacy rate, and adverse reactions were compared between the two groups before and after treatment. Results: The TCM symptom scores of patients in the observation group after treatment were lower than those in the control group, and the difference was statistically significant (P < 0.05). The clinical efficacy rate and incidence of adverse drug reactions in the observation group were superior to those in the control group (95.6% vs 82.1%, 8.8% vs 22%), with the differences being statistically significant (P < 0.05). Conclusion: The Qingfei Huatan Jiedu Formula demonstrates significant clinical efficacy and high safety in the treatment of severe pneumonia with phlegm-heat obstructing the lung syndrome, and is worthy of clinical promotion.